These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10850448)

  • 1. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
    Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
    Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
    Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
    Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
    Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
    Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
    Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
    Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
    Keller G; Schally AV; Nagy A; Halmos G; Baker B; Engel JB
    Cancer; 2005 Nov; 104(10):2266-74. PubMed ID: 16211544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
    Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A
    Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
    Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
    Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
    Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
    Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
    Szepeshazi K; Schally AV; Halmos G; Armatis P; Hebert F; Sun B; Feil A; Kiaris H; Nagy A
    Cancer Res; 2002 Feb; 62(3):781-8. PubMed ID: 11830533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.
    Knoll K; Wrasidlo W; Scherberich JE; Gaedicke G; Fischer P
    Cancer Res; 2000 Nov; 60(21):6089-94. PubMed ID: 11085532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
    Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
    Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
    Plonowski A; Schally AV; Koppan M; Nagy A; Arencibia JM; Csernus B; Halmos G
    Cancer; 2001 Sep; 92(5):1168-76. PubMed ID: 11571730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
    Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
    Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
    Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.